Kyowa Kirin CoKYKOF 82 Pretax Margin % is 26.66% as of Dec. 2025, which is 58% above its 10-year median of 16.90. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 77.7% on this metric.
The historical rank and industry rank for Kyowa Kirin Co's Pretax Margin % or its related term are showing as below:
KYKOF'
s Pretax Margin % Range Over the Past 10 Years
Min: 12.32 Med: 16.9 Max: 24.62
Current: 18.27
KYKOF's Pretax Margin % is ranked better than 77.7% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs KYKOF: 18.27
Kyowa Kirin Co (OTCPK:KYKOF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Kyowa Kirin Co Pretax Margin % Related Terms
Kyowa Kirin Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a Pretax Margin % of 26.66% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Kyowa Kirin Co and its competitors. This is 58% above median its historical median of 16.90. Over the past decade, Kyowa Kirin Co's Pretax Margin % has ranged from 12.32 to 24.62. According to the industry distribution chart, Kyowa Kirin Co ranks #213 out of 955 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is Kyowa Kirin Co's Pretax Margin % too high?
Kyowa Kirin Co's current Pretax Margin % of 26.66% is 58% above median its 10-year median of 16.90. Over the past 10 years, this metric has ranged from a low of 12.32 to a high of 24.62. The Drug Manufacturers industry median Pretax Margin % is 7.28. Kyowa Kirin Co's value of 26.66% is 266.2% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #213 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #213 out of 955 companies for Pretax Margin %. This places Kyowa Kirin Co in the top 22% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Kyowa Kirin Co's value of 26.66% is 266.2% above this benchmark. Historically, Kyowa Kirin Co's own Pretax Margin % has ranged from 12.32 to 24.62 over the past decade. While the company's 10-year median is 16.90 vs. the industry median of 7.28, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Pretax Margin % of 26.66% is 266.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Pretax Margin % is 26.66%, which is 58% above median its own 10-year median of 16.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current Pretax Margin % is 26.66%, which is 58% above median its 10-year median of 16.90 and 266.2% above the Drug Manufacturers industry median of 7.28. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Pretax Margin % is 26.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
Pretax Margin %: 26.66% (58% above median its 10-year median of 16.90)
GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
Industry Position: 266.2% above the Drug Manufacturers median (#213 of 955)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
